Product logins

Find logins to all Clarivate products below.


Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Related Market Assessment Reports

Report
Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…
Report
Prostate Cancer – Unmet Need – Unmet Need – Metastatic Hormone-Sensitive Prostate Cancer (US/EU)
Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…
Report
Prostate Cancer | Disease Landscape & Forecast | G7 | 2024
Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant…
Report
Prostate Cancer – Geographic focus: China – China In-Depth – Prostate Cancer
The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…